Comparison of Survival Between Hypofractionated and Conventional Radiotherapy in Clinically Localized Prostate Cancer: A Single-Center Retrospective Cohort
| Author | Afshin Rakhsha | en |
| Author | Bahram Mofid | en |
| Author | Amir Shahram Yousefi Kashi | en |
| Author | Farzad Taghizadeh-Hesary | en |
| Author | Massumeh Sajjadi rad | en |
| Orcid | Afshin Rakhsha [0000-0001-9601-7074] | en |
| Orcid | Bahram Mofid [0000-0003-2151-3510] | en |
| Orcid | Amir Shahram Yousefi Kashi [0000-0002-0787-2480] | en |
| Orcid | Farzad Taghizadeh-Hesary [0000-0002-6195-2203] | en |
| Orcid | Massumeh Sajjadi rad [0000-0003-4717-7025] | en |
| Issued Date | 2020-07-14 | en |
| Abstract | Background: Prostate cancer (pCa) is the most frequently diagnosed visceral cancer among men. The main role of radical prostatectomy and external-beam radiation therapy (EBRT) in the management of patients with localized pCa has been established. Objectives: This study aims at comparing the clinical outcomes of hypofractionated versus conventional EBRT in the definitive management of patients with localized pCa. Methods: From 2013 to 2019, a consecutive series of patients with localized pCa was treated with conventional (74 Gy at 2 Gy fractions) or hypofractionated (70.2 Gy at 2.7 Gy fractions) radiotherapy schedules, using 3-dimensional conformal radiation therapy (3D-CRT) and intensity-modulated radiation therapy (IMRT), respectively. The impact of the fractionation schedule on biochemical or clinical relapse-free survival (bc-RFS) and overall survival (OS) was assessed. Results: The median follow-up was 42 months (range: 8 - 81 months). Among 170 patients, 81 were treated with conventional and 89 with the hypofractionated schedule. The patient characteristics between groups were comparable. The mean bc-RFS of patients in conventional and hypofractionated groups was 34.9 and 35.4 months, respectively (confidence interval (CI) 95%: 34.5 - 35.7, P = 0.25). Accordingly, the mean OS of patients in conventional and hypofractionated groups was 34.6 and 38.6 months, respectively (CI 95%: 37.3 - 38.6, P = 0.04). The sub-analysis showed that the OS benefit of hypofractionated schedule was limited to intermediate- and high-risk groups with a trend toward significance (CI 95%: 0.02 - 1.46, P = 0.054). Conclusions: Hypofractionation had OS benefit over the conventional schedule for definitive radiotherapy of localized pCa. This benefit was limited to patients with intermediate- and high-risk pCa. | en |
| DOI | https://doi.org/10.5812/ijcm.105762 | en |
| Keyword | Hypofractionation | en |
| Keyword | Radiotherapy | en |
| Keyword | Prostate Cancer | en |
| Keyword | Overall Survival | en |
| Keyword | Relapse-Free Survival | en |
| Publisher | Brieflands | en |
| Title | Comparison of Survival Between Hypofractionated and Conventional Radiotherapy in Clinically Localized Prostate Cancer: A Single-Center Retrospective Cohort | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- ijcm-13-7-105762.pdf
- Size:
- 213.48 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF